Lab guide · Growth-hormone axis
What Is IGF-1 LR3? IGFBP-Resistant IGF-1 Analogue Research Overview
What is IGF-1 LR3? It is an 83-residue recombinant analogue of insulin-like growth factor-1 with a 13-residue N-terminal extension and arginine in place of glutamate at position 3, which together sharply reduce binding to IGF-binding proteins. This guide explains the design, what “long” does and does not mean, and the published findings on potency and receptor binding.
Peamised järeldused
- IGF-1 LR3 has 83 residues (native IGF-1 has 70), formula C400H619N111O115S9 and mass about 9.1 kDa, with the three native disulfide bonds retained.
- Its design lowers affinity for IGF-binding proteins by roughly 1000-fold for IGFBP-3 and IGFBP-4 (Ballard et al., 1993), while receptor binding is reduced about 3-fold (Tomas et al., 1992).
- In rats it was cleared from plasma faster than IGF-1 because it does not associate with plasma binding proteins, so “long” refers to the extension, not to a longer half-life.
- Its main research uses are IGF-1 receptor signalling and cell culture, and it is not an approved medicine.
What is IGF-1 LR3?
So, what is IGF-1 LR3? IGF-1 LR3 (Long R3 IGF-I) is a recombinant analogue of human insulin-like growth factor-1. The variant was described by Francis et al. (1992), who made novel recombinant fusion-protein analogues of IGF-I to assess the relative importance of IGF-binding-protein and receptor binding for enhanced biological potency. In practice it is mostly used as a more potent IGF-1 receptor ligand in cell culture.
Ainult teadusuuringuteks. Käesolev ülevaade võtab kokku avaldatud laboratoorsed ja loomkatsed. Baltic Peptides tarnib seda ühendit kvalifitseeritud teadlaste poolt läbiviidavateks in vitro ja prekliinilisteks uuringuteks; see ei ole ravim ega ole mõeldud kasutamiseks inimestel ega loomadel.
Keemiline struktuur ja tehnilised andmed
| Kinnisvara | Väärtus |
|---|---|
| Pikkus | 83 residues (native IGF-1: 70) |
| Changes vs IGF-1 | N-terminal extension MFPAMPLSSLFVN plus Glu3→Arg |
| Disulfide bonds | Kolm (loomulik IGF-1-mustri järgi) |
| Molekulivalem | C400H619N111O115S9 |
| Molekulmass | ≈9111.5 Da (average, with three disulfides) |
| CAS-number | 946870-92-4 (supplier-listed) |
I confirmed that the 83-residue sequence, with three disulfide bonds, reproduces the formula and mass. The nine sulfur atoms come from six cysteines and three methionines. Because it is a folded protein, a mass check alone cannot show that the disulfides are paired correctly, which is why bioactivity assays are used alongside HPLC and mass spectrometry.
Avastamise ja uurimistöö ajalugu
The analogues came from CSIRO laboratories in Adelaide, South Australia, where Francis, Ballard and colleagues studied how IGF-binding proteins limit IGF-I action. In the 1992 rat study from the same group, Tomas et al. found that two analogues that bind poorly to IGFBPs, des(1-3)IGF-I and LR3IGF-I, were about 2.5-fold more potent than IGF-I in dexamethasone-treated rats.
LR3 has since become a standard supplement in serum-free mammalian cell culture, because cells secrete IGFBPs that would otherwise sequester native IGF-1.
Mechanism: IGFBP escape and receptor activation
Binding proteins
IGFBPs sequester IGFs away from the type 1 IGF receptor and can inhibit IGF-stimulated mitogenesis, differentiation and survival, as Firth and Baxter (2002) review. IGF-1 has about 1000-fold higher affinity than LR3IGF-I for IGFBP-3, IGFBP-4 and total rat plasma binding proteins (Ballard et al., 1993).
Receptor binding and the “long” misnomer
Tomas et al. noted that LR3IGF-I binds about 3-fold less well than IGF-I to the type 1 IGF receptor, yet was striking in vivo. Ballard and colleagues found that LR3IGF-I was removed from plasma much more rapidly than IGF-I because it does not associate with plasma IGFBPs. “Long” refers to the extended sequence, so the analogue is more potent in IGFBP-rich settings but shorter-lived in rat plasma.
Peamised uurimisvaldkonnad
- IGF-1 receptor signalling: PI3K/Akt/mTOR and Ras/MAPK activation in cell models.
- IGFBP biology: separating receptor-driven from binding-protein-mediated effects by comparison with native IGF-1.
- Cell culture and bioprocessing: serum-free media supplementation.
- Muscle cell biology: myoblast proliferation and differentiation in vitro.
Mida avaldatud uuringud tegelikult näitavad
| Tõendite liik | Millest teatatakse |
|---|---|
| Keemilised faktid | Sequence length, extension, Arg3 change and formula are verifiable. |
| Binding studies | About 1000-fold lower IGFBP-3 and IGFBP-4 affinity and about 3-fold lower receptor affinity than IGF-I. |
| Rat studies | About 2.5-fold greater potency than IGF-I in dexamethasone-treated rats (Tomas et al., 1992); faster plasma clearance than IGF-I. |
| Regulatiivne | Not an approved medicine. The licensed IGF-1 product, mecasermin, is a native-sequence rhIGF-1, according to the supplier product page. |
Potency depends on the system. It is most striking where IGFBPs are abundant and smaller where they are absent.
Teaduslikud piirangud ja lahtised küsimused
- Potency gains are model-dependent and not a statement about outcomes outside experimental systems.
- Proper folding and disulfide pairing cannot be confirmed by mass alone.
- Receptor activation has mitogenic consequences, so experimental concentrations and cell types matter.
- It is not approved as a medicine, and IGF-1 and its analogues are on the WADA Prohibited List according to the supplier product page.
Analüütilised ja laboratoorsed aspektid
Intact-mass analysis should show about 9111.5 Da. SDS-PAGE and reverse-phase HPLC check purity, and a receptor-binding or cell-proliferation assay confirms bioactivity, since a protein can be pure but misfolded. Endotoxin matters for cell-culture work. As a folded protein, it is sensitive to freeze-thaw cycling, vigorous agitation and adsorption to plastic at low concentrations.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the IGF-1 LR3 product page.
Allikad ja täiendav kirjandus
- Francis G.L. et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 8(3):213-223. DOI
- Tomas F.M. et al. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 282:91-97. PMC full text
- Ballard F.J. et al. (1993). Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regul 3(1):40-44. PubMed
- Firth S.M. and Baxter R.C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23(6):824-854. PubMed
Kõik „ Baltic Peptides ” tooted on mõeldud kasutamiseks üksnes laboratoorsetes uuringutes. Need ei ole ravimid, toidulisandid ega toiduained ning neid ei tohi kasutada inimeste ega loomade puhul. Käesolev artikkel võtab kokku avaldatud uuringud üksnes hariduslikel eesmärkidel ega kirjeldada nende kasutamist inimeste puhul.
KKK
Korduma kippuvad küsimused
What is IGF-1 LR3?
What does LR3 stand for?
What is the molecular weight and formula of IGF-1 LR3?
Kuidas erineb IGF-1 LR3 looduslikust IGF-1-st?
Does Long R3 mean a longer half-life?
Why is IGF-1 LR3 used in cell culture?
Is IGF-1 LR3 an approved medicine?
Loe edasi
Soovitatav lugemine
IGF-1 LR3
Current batches, formats and the COA for IGF-1 LR3.
What is AOD-9604?
A growth-hormone fragment studied separately from the IGF-1 axis.
Kuidas peptiidi lugeda COA
The checklist for any certificate of analysis.
Research-grade IGF-1 LR3, tested before it ships
Iga EList väljasaadetud partii kohta on esitatud sõltumatu laboratooriumi HPLC ja massispektromeetria tulemused.
